Dechra Pharmaceuticals

Equities

DPH

GB0009633180

Delayed London S.E. Other stock markets 02:30:00 2024-01-16 am EST			5-day change	1st Jan Change
3,866 ^GBX	-.--%		-.--%	+0.21%

Apr. 11	Dechra Pharmaceuticals Limited reached agreement in principle to acquire 33.34% stake in STEM Animal Health Inc. for $4.7 million.	CI
Apr. 09	Dechra Group Holdings Limited Appoints Paul Nicholas Sandland as Director	CI

Dechra Pharmaceuticals : Merlin Entertainments names Anne-Francoise Nesmes as new CFO

February 16, 2016 at 02:26 am EST

LONDON (Reuters) - Merlin Entertainments (>> Merlin Entertainments PLC), the operator of Sea Life centres and Legoland theme parks in Europe, North America and Asia, named Anne-Francoise Nesmes as its new chief financial officer from Aug. 1.

Nesmes joins from veterinary medical supplier Dechra Pharmaceuticals (>> Dechra Pharmaceuticals plc), where she had been CFO since 2013. She will replace Andrew Carr, who announced his intention to retire in January.

Merlin Entertainments is trying to boost visitor numbers to its Alton Tower theme park in Britain after an accident last year left four teenagers seriously injured. It has since put in place improved safety-measures at all its roller-coasters.

(Reporting by Sarah Young, Editing by Paul Sandle)

Stocks treated in this article : Dechra Pharmaceuticals plc, Merlin Entertainments PLC

Latest news about Dechra Pharmaceuticals

Dechra Pharmaceuticals Limited reached agreement in principle to acquire 33.34% stake in STEM Animal Health Inc. for $4.7 million.	Apr. 10	CI
Dechra Group Holdings Limited Appoints Paul Nicholas Sandland as Director	Apr. 09	CI
Dechra Group Holdings Limited Appoints Ian David Page as Director	Apr. 09	CI
Dechra Group Holdings Limited Announces Resignation of Thomas Spicer as Director	Apr. 09	CI
Dechra Group Holdings Limited Announces Resignation of Anthony Santospirito as Director	Apr. 09	CI
Dechra Group Holdings Limited Announces Resignation of Sara Huda as Director	Apr. 09	CI
Stocks slump as Fed rate cut hope dwindles	Jan. 17	AN
Dechra Pharmaceuticals Delists From London Bourse Following Freya Bidco’s Takeover	Jan. 17	MT
EQT's Freya Bidco Completes Dechra Pharmaceuticals Purchase	Jan. 16	MT
Dechra Pharmaceuticals PLC(LSE:DPH) dropped from FTSE 100 Index	Jan. 16	CI
Dechra Pharmaceuticals PLC(LSE:DPH) dropped from FTSE All-World Index	Jan. 16	CI
Dechra Pharmaceuticals PLC(LSE:DPH) dropped from FTSE 350 Index	Jan. 16	CI
Dechra Pharmaceuticals PLC(LSE:DPH) dropped from FTSE All-Share Index	Jan. 16	CI
Dechra Pharmaceuticals PLC(LSE:DPH) dropped from FTSE 350 (Ex Investment Companies) Index	Jan. 16	CI
Dechra Pharmaceuticals PLC(LSE:DPH) dropped from S&P Global BMI Index	Jan. 16	CI
EQT X EUR SCSp and EQT X USD SCSp managed by Eqt Fund Management S.à R.L. and Luxinva SA (the Offerors) completed the acquisition of Dechra Pharmaceuticals PLC.	Jan. 15	CI
Persimmon to replace outbound FTSE 100 constituent Dechra	Jan. 12	AN
EMEA Morning Briefing : Markets to Track Fresh Middle East Tensions	Jan. 12	DJ
EU clears Dechra Pharmaceuticals takeover by EQT funds	Dec. 27	AN
EQT's Dechra Takeover to Become Effective in Mid-January 2024	Dec. 27	MT
EQT's Takeover of Dechra Pharmaceuticals Gets EU Antitrust Regulator's Nod	Dec. 22	MT
Inchcape to appoint Jerry Buhlmann to chair board of directors from May	Dec. 14	AN
EQT Secures Australian Nod for Dechra Pharmaceuticals Takeover	Nov. 30	MT
FTSE 100 Ends Down, Falling Behind European Peers	Nov. 29	DJ
Hargreaves Lansdown picks Dechra chair Alison Platt as chair	Nov. 29	AN

Chart Dechra Pharmaceuticals

Duration

Period

More charts

Company Profile

Dechra Pharmaceuticals PLC specializes in the manufacturing and marketing of veterinary pharmaceutical products. Net sales break down by family of products as follows: - companion animal products (74.6%); - food producing animal products (11.5%); - equine health products (7.3%); - animal feeds (5.1%); - other (1.5%): products manufactured by third parties. Net sales are distributed geographically as follows: the United Kingdom (8.5%), Germany (9.2%), Europe (31.2%), the United States (37.9%) and other (13.2%).

Sector

More about the company